The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts, including over 800 and 170 patients that have been treated for more than 24 and 72 weeks, respectively. This fifth DMC review confirms the good safety profile of lanifibranor. Daix (France) ...